On September 13^th, Richter BioLogics GmbH & Co KG, the microbial biologics affiliate of Gedeon Richter Plc., celebrated the opening of its new biopharmaceutical cGMP facility in Bovenau.
 
The new production facility was inaugurated by Daniel Günther, Minister-President of the State of Schleswig-Holstein; Daniel Ambrock, Mayor of Bovenau; and on behalf of the Gedeon Richter Group: Erik Bogsch – Lifetime Honorary Chairman; Dale Martin – Member of the Supervisory Board; Dr. Erik Bogsch – Head of the Biotechnology Business Unit; Dr. Kai Pohlmeyer, CEO; and Johannes Salzbrunn, COO of Richter Biologics. Guests from local government, authorities and scientific community, together with business partners and employees of Richter BioLogics and Gedeon Richter Plc, celebrated the grand opening.
 
“Putting the plant into operation represents a major milestone in the implementation of Richter BioLogics’ growth strategy,” said Dr. Kai Pohlmeyer, Managing Director at Richter BioLogics. “With one of Richter’s largest investments in the last decade, we have positioned ourselves as a key player in meeting global market demand and supplying the global pharmaceutical industry with the highest quality biopharmaceutical products. We also increase our flexibility, one of our biggest and most valued strengths.”
 
The cGMP facility is equipped with the latest technology for clinical and large-scale commercial production and market supply of protein-based and plasmid DNA-based products.
 
The new multi-purpose GMP facility increases the total manufacturing area to approximately 10,000 square meters. The new 300L and 1500L production lines provide further flexibility to manufacture different products simultaneously, allowing up to 120 batches per year. Additional space is being created for future growth. The facility also includes large laboratories for analytical testing, warehousing and technical areas to optimize the flow of people and materials. By the end of 2024, the number of highly skilled local employees is expected to double to more than 400.
 
“This investment demonstrates a strong commitment to the future of Richter BioLogics, to innovation and to GMP manufacturing of biopharmaceuticals made in Germany and to Richter’s commitment to biological products. This new facility together with our existing facilities in Hungary provide for a fully integrated R&D and manufacturing biologics capability, allowing for further access to such medicines to patients worldwide,” said Dr. Erik Bogsch, Head of the Biotechnology Business Unit of Gedeon Richter.